FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a means for correction of states of cells, different organs and tissues, as well as human organs and tissues, related to quantitative decrease of protein of collagen type i alpha 2 chain, based on genetic-therapeutic substances with the COL1A2 gene, where the cells of organs and tissues are selected from fibroblasts, keratocytes, chondroblasts and epithelial cells of the eye cornea, organs and tissues are selected from skin, cartilage tissue or muscle tissue of a person, representing at least one genetic-therapeutic substance, selected from the group of genetic therapeutic substances, each of which is a genetic construct based on a vector plasmid, containing the native complementary DNA of the COL1A2 gene SEQ ID №: 1 or a modified complementary DNA of the COL1A2 gene, wherein the modified complementary DNA of the COL1A2 gene is SEQ ID No: 2, or SEQ ID No: 3, or SEQ ID No: 4, or SEQ ID No: 5, or SEQ ID No: 6, or SEQ ID No: 7, combination of these genetic constructs, each of which also contains regulatory elements in combination with or without a transport molecule. Group of inventions also relates to a method for producing said agent for treating human body states, related to quantitative decrease of protein of collagen type i alpha 2 chain, based on genetic-therapeutic substances with the COL1A2 gene; method for using said agent for treating human body states related to decreased expression of the COL1A2 gene and/or decreased activity of the catalase protein.
EFFECT: group of inventions provides a high and stable level of the target protein in the cells.
5 cl, 18 ex, 20 dwg
